Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.26 (
GSK
)
6,788
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
WNT-7a induces axonal spreading and branching in developing cerebellar granule neurons. This effect is mediated through the inhibition of
GSK
-3beta, a serine/threonine kinase and a component of the WNT pathway. Lithium, an inhibitor of
GSK
-3beta, mimics WNT-7a in granule cells. Here we examined further the effect of
GSK
-3beta inhibition on cytoskeletal re-organisation. Lithium induces axonal spreading and increases growth cone area and perimeter. This effect is associated with the absence or reduction of stable microtubules in spread areas. Lithium induces the loss of a phosphorylated form of
MAP-1B
, a microtubule associated protein involved in axonal outgrowth. Down-regulation of the phosphorylated
MAP-1B
,
MAP-1B
-P, from axonal processes occurs before axonal remodelling is evident. In vitro phosphorylation assays show that
MAP-1B
-P is generated by direct phosphorylation of
MAP-1B
by
GSK
-3beta. WNT-7a, like lithium, also leads to loss of
MAP-1B
-P from spread axons and growth cones. Our data suggest that WNT-7a and lithium induce changes in microtubule dynamics by inhibiting
GSK
-3beta which in turn lead to changes in the phosphorylation of
MAP-1B
. These findings suggest a novel role for
GSK
-3beta and WNTs in axonal remodelling and identify
MAP-1B
as a new target for
GSK
-3beta and WNT.
...
PMID:Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. 957 Jul 53
Valproate (VPA) and lithium have been used for many years in the treatment of manic depression. However, their mechanisms of action remain poorly understood. Recent studies suggest that lithium and VPA inhibit
GSK
-3beta, a serine/threonine kinase involved in the insulin and WNT signaling pathways. Inhibition of
GSK
-3beta by high concentrations of lithium has been shown to mimic WNT-7a signaling by inducing axonal remodeling and clustering of synapsin I in developing neurons. Here we have compared the effect of therapeutic concentrations of lithium and VPA during neuronal maturation. VPA and, to a lesser extent, lithium induce clustering of synapsin I. In addition, lithium and VPA induce similar changes in the morphology of axons by increasing growth cone size, spreading, and branching. More importantly, both mood stabilizers decrease the level of
MAP-1B
-P, a
GSK
-3beta-phosphorylated form of
MAP-1B
in developing neurons, suggesting that therapeutic concentrations of these mood stabilizers inhibit
GSK
-3beta. In vitro kinase assays show that therapeutic concentrations of VPA do not inhibit
GSK
-3beta but that therapeutic concentrations of lithium partially inhibit
GSK
-3beta activity. Our results support the idea that both mood stabilizers inhibit
GSK
-3beta in developing neurons through different pathways. Lithium directly inhibits
GSK
-3beta in contrast to VPA, which inhibits
GSK
-3beta indirectly by an as-yet-unknown pathway. These findings may have important implications for the development of new strategies to treat bipolar disorders.
...
PMID:Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. 1209 58
Familial Alzheimer's Disease (AD) has been linked to amyloid beta protein precursor (AbetaPP) and presenilin gene mutations. In sporadic AD, which accounts for the vast majority of cases, the pathogenesis of neurodegeneration is unknown; however, recent evidence suggests a role for oxidative stress. The present study demonstrates that transient hypoxic injury to cortical neurons causes several of the molecular and biochemical abnormalities that occur in AD including, mitochondrial dysfunction, impaired membrane integrity, increased levels of DNA damage, reactive oxygen species, phospho-tau, phospho-
MAP-1B
, and ubiquitin immunoreactivity, and AbetaPP cleavage with accumulation of Abeta-immunoreactive products. These abnormalities were associated with activation of kinases that phosphorylate tau, including glycogen synthase kinase 3beta (GSK-3beta), mitogen-activated protein kinase (MAPK), and cyclin-dependent kinase 5 (Cdk-5). Further studies showed that significant neuro-protection with sparing of mitochondrial function and membrane integrity could be achieved by pre-treating the cortical neurons with N-acetyl cysteine, glutathione, or inhibitors of
GSK
-3beta, MAP kinase, or AbetaPP gamma-secretase. Therefore, in the absence of underlying gene mutations, oxidative stress can cause AD-type abnormalities, including aberrant post-translational processing of neuronal cytoskeletal proteins and APP. Our results also suggest that pre-treatment with agents that block specific components of the AD neurodegeneration cascade may provide neuroprotection against oxidative stress-induced impairments in membrane integrity, mitochondrial function, and viability.
...
PMID:Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection. 1475 39
Dishevelled (DVL) is associated with axonal microtubules and regulates microtubule stability through the inhibition of the serine/threonine kinase, glycogen synthase kinase 3beta (GSK-3beta). In the canonical WNT pathway, the negative regulator Axin forms a complex with beta-catenin and
GSK
-3beta, resulting in beta-catenin degradation. Inhibition of
GSK
-3beta by DVL increases beta-catenin stability and TCF transcriptional activation. Here, we show that Axin associates with microtubules and unexpectedly stabilizes microtubules through DVL. In turn, DVL stabilizes microtubules by inhibiting
GSK
-3beta through a transcription- and beta-catenin-independent pathway. More importantly, axonal microtubules are stabilized after DVL localizes to axons. Increased microtubule stability is correlated with a decrease in
GSK
-3beta-mediated phosphorylation of
MAP-1B
. We propose a model in which Axin, through DVL, stabilizes microtubules by inhibiting a pool of
GSK
-3beta, resulting in local changes in the phosphorylation of cellular targets. Our data indicate a bifurcation in the so-called canonical WNT-signaling pathway to regulate microtubule stability.
...
PMID:A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. 1473 35